Welcome to our dedicated page for NeueHealth news (Ticker: BHG), a resource for investors and traders seeking the latest updates and insights on NeueHealth stock.
NeueHealth, Inc. (BHG) drives innovation in value-based care through integrated health solutions and digital-first insurance models. This news hub provides investors and industry stakeholders with timely updates on the company’s strategic initiatives, operational milestones, and healthcare technology advancements.
Access official press releases and curated analysis covering NeueHealth’s partnerships with health systems, product developments, and regulatory engagements. Our repository simplifies tracking of earnings announcements, leadership updates, and emerging trends in connected care ecosystems.
Discover how BHG’s subscription-based insurance models and patient engagement tools evolve through verified updates. Bookmark this page for efficient monitoring of NeueHealth’s progress in bridging healthcare accessibility gaps via technology-driven solutions.
NeueHealth (NYSE: NEUE) reported solid Q2 2024 results, delivering positive Adjusted EBITDA for the second consecutive quarter. The company reaffirmed its full-year Adjusted EBITDA guidance and expects to reach the high end of its guidance range for consumers served by year-end. Key metrics include:
- Revenue: $225,991,000 (Q2 2024) vs $297,982,000 (Q2 2023)
- Net Loss: $57,698,000 (Q2 2024) vs $88,627,000 (Q2 2023)
- Adjusted EBITDA: $3,962,000 (Q2 2024) vs $7,797,000 (Q2 2023)
For 2024, NeueHealth projects:
- Revenue: ~$950 million
- NeueCare Revenue: ~$320 million
- NeueSolutions Revenue: ~$640 million
- Adjusted EBITDA: $15-25 million
The company continues to focus on advancing its value-driven model and delivering high-quality, consumer-centric care across ACA Marketplace, Medicare, and Medicaid populations.
NeueHealth, Inc. (NYSE: NEUE), a value-driven healthcare company, has announced its Second Quarter 2024 earnings conference call scheduled for August 7, 2024. The company will release its financial results before the markets open, followed by a conference call at 8:00 AM Eastern Time. Participants are encouraged to pre-register for the call and dial in at least 15 minutes early. A webcast of the earnings call will be accessible via NeueHealth's Investor Relations page, and a recording of the call and presentation will be available afterward on the same platform.
NeueHealth has secured a term loan facility for up to $150 million with Hercules Capital, significantly strengthening its balance sheet. This financing aims to advance NeueHealth's differentiated care model and support the company's strategic priorities in 2024 and beyond. The loan will help NeueHealth deliver value-driven, consumer-centric care across the ACA Marketplace, Medicare, and Medicaid. Both companies expressed optimism about the partnership's potential to drive value for payors, providers, and consumers.
NeueHealth announced it received a non-compliance letter from the NYSE on June 12, 2024. This notice states that the company failed to meet the continued listing standards due to its average market capitalization falling below $50 million over a 30 trading-day period and a stockholders’ deficit. As of June 11, 2024, NeueHealth's average market capitalization was approximately $49.7 million. The company's preferred stock, valued at $920.4 million as of March 31, 2024, is excluded from this calculation. The company's operations remain unaffected, and it has 45 days to submit a compliance plan to the NYSE. Pending NYSE's acceptance, the company has an 18-month period to regain compliance. During this period, NeueHealth will continue to trade under the symbol 'NEUE' with a '.BC' designation.
NeueHealth, Inc. reported strong Q1 '24 results with Revenue of $245.1 million, Net Income of $5.7 million, and Adjusted EBITDA of $2.5 million. They focus on consumer-centric care, provider partnerships, and consumer engagement. Revenue guidance for 2024 is around $1 billion, with expected segment revenues of $310-320 million for NeueCare and $690-700 million for NeueSolutions. The company aims for an Adjusted EBITDA of $15-25 million in 2024.
FAQ
What is the market cap of NeueHealth (BHG)?
